US 12,071,644 B2
Xylanase variants and methods
Jie Yang, Foster City, CA (US); William Buchanan Porterfield, Oakland, CA (US); Xiyun Zhang, San Ramon, CA (US); Goutami Banerjee, Daly City, CA (US); Khin Oo, Daly City, CA (US); and Wenhua Lu, Dublin, CA (US)
Assigned to Fornia Biosolutions, Inc., Hayward, CA (US)
Filed by Fornia BioSolutions, Inc., Hayward, CA (US)
Filed on Dec. 16, 2021, as Appl. No. 17/552,423.
Claims priority of provisional application 63/126,832, filed on Dec. 17, 2020.
Prior Publication US 2022/0195410 A1, Jun. 23, 2022
Int. Cl. C12N 9/24 (2006.01); A23K 20/189 (2016.01); A23K 50/30 (2016.01); A23K 50/75 (2016.01); C12N 15/63 (2006.01)
CPC C12N 9/248 (2013.01) [C12N 15/63 (2013.01); A23K 20/189 (2016.05); A23K 50/30 (2016.05); A23K 50/75 (2016.05)] 28 Claims
 
1. A composition comprising:
a variant xylanase enzyme comprising: at least one amino acid substitution as compared to SEQ ID NO:1, wherein said amino acid substitution is at a position number selected from the group consisting of 1, 2, 5, 6, 8, 12, 15, 18, 20, 23, 25, 26, 27, 28, 35, 38, 51, 52, 54, 56, 86, 89, 90, 93, 99, 105, 119, 120, 121, 131, 133, 135, 149, 160, 168, 178, 185, 190, 194, 201, 224, and 225, and wherein said variant enzyme is at least 90% identical to SEQ ID NO:1, and wherein the amino acid substitution at the position number of 160 is N160Q or N160R;
a variant xylanase enzyme comprising: at least two amino acid substitutions as compared to SEQ ID NO:1 comprising an amino acid substitution at position number 18 and at least one more amino acid substitution at a position number selected from the group consisting of 1, 2, 5, 6, 8, 12, 15, 20, 23, 25, 26, 27, 28, 35, 38, 51, 52, 54, 56, 86, 89, 90, 93, 99, 105, 119, 120, 121, 131, 133, 135, 149, 160, 168, 178, 185, 190, 194, 201, 224, and 225, wherein said variant enzyme is at least 90% identical to SEQ ID NO:1, and wherein the amino acid substitution at the position number of 160 is N160Q or N160R;
a variant xylanase enzyme comprising: at least two amino acid substitutions as compared to SEQ ID NO:1 comprising an amino acid substitution at position number 160 and at least one more amino acid substitution at a position number selected from the group consisting of 1, 2, 5, 6, 8, 12, 15, 20, 23, 25, 26, 27, 28, 35, 38, 51, 52, 54, 56, 86, 89, 90, 93, 99, 105, 119, 120, 121, 131, 133, 135, 149, 168, 178, 185, 190, 194, 201, 224, and 225, wherein said variant enzyme is at least 90% identical to SEQ ID NO:1; or
a variant xylanase enzyme comprising: at least three amino acid substitutions as compared to SEQ ID NO 1, comprising an amino acid substitution at position number 18, an amino acid substitution at position number 160, and at least one more amino acid substitution at a position number selected from the group consisting of 1, 2, 5, 6, 8, 12, 15, 20, 23, 25, 26, 27, 28, 35, 38, 51, 52, 54, 56, 86, 89, 90, 93, 99, 105, 119, 120, 121, 131, 133, 135, 149, 168, 178, 185, 190, 194, 201, 224, and 225, wherein said variant enzyme is at least 90% identical to SEQ ID NO:1; and
further comprising an amino acid substitution at position 131 which is H131F.